health care:
FDA approves drug tested at Nevada Cancer Institute
Thursday, April 9, 2009 | 1:40 p.m.
Map of Nevada Cancer Institute
Nevada Cancer Institute
One Breakthrough Way, Las Vegas
Related link
A new cancer drug studied in clinical trials by a Nevada Cancer Institute doctor has been approved by the U.S. Food and Drug Administration.
Dr. Nicholas Vogelzang, professor and chief of genitourinary oncology, led the study of Afinitor tablets, a kidney drug for patients with advanced renal cell carcinoma, which is cancer that arises in the lining of internal organs. Doctors would turn to this medicine after other drugs failed.
“What this means for kidney cancer patients, not only locally but nationally, is that there is another treatment option available for them when other regimens have not been successful,” said Dr. James Symanowski, senior biostatistician and interim head of the institute’s Clinical Trials Office.
Afinitor, created by the pharmaceutical company Novartis, is the first FDA-approved, once-daily pill treatment that targets a protein inside the cancer cell that controls tumor cell division and blood vessel growth.
The Nevada Cancer Institute, 1 Breakthrough Way in Summerlin, was one of the sites that tested this new drug on four Las Vegas patients.
Randy Irwin was one of those patients. He said he was excited to take part in a clinical trial that brought the drug to approval.
“It makes me proud that I was able to help others, both now and in the future,” he said.
Vogelzang said clinical trials such as those at the institute allow Nevadans access to the latest in cancer treatment.
In the U.S., kidney cancer accounts for about 3 percent of all adult cancers. Renal cell carcinoma is the most common type of kidney cancer, with rates rising steadily around the world due in part to smoking and obesity. About 54,000 new cases developed in the U.S. in 2008, and more than 13,000 people died from the disease.
For more information, visit www.nevadacancerinstitute.org or call 822-LIFE.
Spotlight
Email Edition
- Most Read
- Discussed
- Most E-mailed
- Ritz-Carlton Lake Las Vegas to close in May
- Pricey land buy on Strip a bit of a surprise
- Engineering marvel taking shape near Hoover Dam
- Harry Reid’s co-writer unloads while discussing polls, Obama quote
- Police: Legal runner returned to home, shot husband and wife
- Grim numbers show Nevada leads nation in suicides over 60
- The 10 best steakhouses in Las Vegas
- UNLV back in the polls: No. 23 in AP, No. 25 in ESPN/USA Today
- MGM Mirage to leave N.J. in dispute over Macau partner
- GOP should blame itself for deficit, not Democrats
Blogs
Politics: Ralston's Flash
Miners sue to block mining tax initiative (3 Comments)
Shark Bytes
Willis reminds me of another great UNLV guard (5 Comments)
Elsewhere
With aggressive push, Internet gambling again in play
The Kats Report
A very quick list of which females could replace Steven Tyler in Aerosmith (18 Comments)
A 3.5-day sprint, highlighted superflously at Flamingo with Las Vegas newcomers
Politics: Ralston's Flash
Horsford: No taxes now, but tax reform later (14 Comments)
Gibbons: Cutting the budget can help me raise money (12 Comments)
Calendar »
- 10 Wed
- 11 Thu
- 12 Fri
- 13 Sat
- 14 Sun
-
Harlem Globetrotters at The Orleans Arena
Orleans Hotel-Casino
-
House of Lounge giveaway at Wasted Space
Wasted Space | 10 p.m. to 11:59 p.m.
-
Rakim at LAX
LAX Nightclub | 10 p.m. to 11:59 p.m.
-
Gilley's Casting Call at Treasure Island
Treasure Island Hotel and Casino
-
Freddy B and Mike Remedy at Blush
Blush Boutique Nightclub | 10 p.m. to 11:59 p.m.
-
Blushing at Blue Martini
Blue Martini | 8 p.m. to 11:59 p.m.
The Sun
Locally owned and independent for more than 50 years.
Technorati




















Post a comment
Commenting requires registration.
Comments are moderated by Las Vegas Sun editors. Our goal is not to limit the discussion, but rather to elevate it. Comments should be relevant and contain no abusive language. Comments that are off-topic, vulgar, profane or include personal attacks will be removed. Full comments policy.
If you would like to submit your comment as a letter to the editor, you may submit it here.